Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL

Bone Marrow Transplantation

Volumn 29, Issue 9, 2002, Pages 769-775

  Flohr, T ^a   Hess, G ^a   Kolbe, K ^a   Gamm, H ^a   Nolte, H ^a   Stanislawski, T ^a   Huber, C ^a   Derigs, H G ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

B NHL; High dose therapy; Immune reconstitution; Purging; Rituximab

Indexed keywords

AMPHOTERICIN B; ANTIVIRUS AGENT; CARMUSTINE; CD20 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; MELPHALAN; OFLOXACIN; RITUXIMAB; VIRUS ANTIGEN;

ADULT; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BONE MARROW PURGING; CANCER RECURRENCE; CANCER SURVIVAL; CELL SELECTION; CELL SORTER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LEUKEMIA REMISSION; LYMPHOCYTE DEPLETION; MALE; MANTLE CELL LYMPHOMA; MORTALITY; NONHODGKIN LYMPHOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW PURGING; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNE SYSTEM; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; REMISSION INDUCTION; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; VIRUS ACTIVATION;

EID: 85047697458     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703515     Document Type: Article

References (35)

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
2. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - A groupe d'Etude des lymphomes de l'Adulte study
3. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis
4. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
5. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
6. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
7. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
8. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma
9. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
10. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
11. Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma
12. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
13. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
14. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
15. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation
16. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma
17. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device
18. The ISHAGE guidelines for CD34+ cell determination by flow cytometry
19. 1997 revised guidelines for performing CD4+ T-cell determination in persons infected with human immunodeficiency virus
20. Immunolgic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
21. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
22. Nonparametric estimation for incomplete observations
23. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
24. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion
25. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation
26. Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF
27. Fatal cytomegalovirus interstitial pneumonia following autologous peripheral blood stem cell transplantation
28. Poor lymphocyte recovery following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
29. Cytomegalovirus colitis after autologous transplantation for multiple myeloma
30. Adjuvant Rituximab after autologous perhiperal blood stem cell transplantation results in delayed immune reconstitution without increase in infectious complications
31. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation
32. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus
33. Cytomegaloviremia after autografting for leukemia: Clinical significance and lack of effect on engraftment
34. Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: No need for surveillance
35. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation